Autopsy report · NCT04411082

A Study of IMR-687 in Subjects With Beta Thalassemia

“IMR-BTL-201demonstrated that while IMR-687 was generally well-tolerated, it failed to show any meaningful benefit in transfusion burden or improvement in most disease-related biomarkers. So, the sponsor has decided to discontinue this study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 1 year 7 months before it stopped.
• 122 participants enrolled.
• Results were posted on the registry 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Cardurion Pharmaceuticals, Inc.

Sponsor type

Industry

Conditions

β Thalassemia

Interventions

IMR-687; Placebo

Participants

122

Sites

36

Countries

Denmark, France, Georgia, Greece, Israel, Italy, Lebanon, Malaysia, Morocco, Netherlands, Tunisia, Turkey (Türkiye) and more

Trials that died the same way

• Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors
  “The sponsor has decided to terminate this study based on the current clinical research status of dual antibody drugs and full communication with the investigators.” (57% match in meaning)
• A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
  “The Sponsor terminated the study due to early dose-limiting toxicities.” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.